Overview

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Collaborators:
Eli Lilly and Company
National Center for Complementary and Integrative Health (NCCIH)
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Citalopram
Dexetimide
Duloxetine Hydrochloride
Venlafaxine Hydrochloride